Proinflammatory cytokines and treatment of disease

Annals of the New York Academy of Sciences

Volumn 856, Issue , 1998, Pages 243-251

  Van Der Meer, Jos W M ^a   Vogels, Maria T E ^a   Netea, Mihai G ^a   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CYTOKINE; CYTOKINE RECEPTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; CONFERENCE PAPER; CYTOKINE PRODUCTION; GRANULOCYTOPENIA; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; MICROBIAL GROWTH; MORTALITY; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 0031772650     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb08331.x     Document Type: Conference Paper

References (59)

1. DUFF, G. W. & S. K. DURUM. 1982. Fever and immunoregulation: Hyperthermia, interleukins 1 and 2, and T-cell proliferation. Yale J. Biol. Med. 55:437-442.
2. DINARELLO, C. A., P. CONTI & J. W. MIER. 1986. Effects of human interleukin-1 on natural killer cell activity: Is fever a host defense mechanism for tumor killing? Yale J. Biol. Med. 59:97-106.
3. DINARELLO, C. A. 1988. Interleukin-1. FASEB J. 2:108-115.
4. TARGAN, S. R., S. B. HANAUER, S. H. J. VAN DEVENTER, L. MAYER, D. H. PRESENT, T. BRAAKMAN, K. L. DEWOODY, T. F. SCHAIBLE & P. J. RUTGEERTS. 1997. A short term study of chimeric monoclonal antibody Ca2 to tumor necrosis factor-α for Crohn's disease. N. Engl. J. Med. 337:1029-1035.
5. FISHER, C. J., JR., J. M. AGOSTI, S. M. OPAL, S. F. LOWRY, R. A. BALK, J. C. SADOFF, E. ABRAHAM, R. M. SCHEIN, E. BENJAMIN & THE SOLUBLE TNF RECEPTOR SEPSIS STUDY GROUP. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fe fusion protein. N. Engl. J. Med. 334:1697-1702.
6. ABRAHAM, E., R. WUNDERINK, H. SILVERMAN, T. M. PERL, S. NASRAWAY, H. LEVY, R. BONE, R. P. WENZEL, R. BALK, R. ALLRED & TNF-A MAB SEPSIS STUDY GROUP. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273:934-941.
7. BONE, R. C. 1996. Why sepsis trials fail. JAMA 276:565-566.
8. ELLIOTT, M. J., R. N. MAINI, M. FELDMANN, J. R. KALDEN, C. ANTONI, J. S. SMOLEN, B. LEEB, F. C. BREEDVELD, J. D. MACFARLANE, H. BIJL et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110.
9. VAN DEVENTER, S. J. 1997. Tumour necrosis factor and Crohn's disease. Gut 40:443-448.
10. NACY, C. A., A. I. MEIEROVICS, M. BELOSEVIC & S. J. GREEN. 1991. Tumor necrosis factor-alpha: Central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology 59:182-184.
11. KINDLER, V., A. P. SAPPINO, G. E. GRAU, P. F. PIGUET & P. VASSALI. 1989. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731-740.
12. ECHTENACHER, B., W. FALK, D. N. MANNEL & P. H. KRAMMER. 1990. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145:3762-3766.
13. GALLIN, J. I., H. L. MALECH, D. A. MELNICK & AND THE INTERNATIONAL CHRONIC GRANULOMATOUS DISEASE COOPERATIVE STUDY GROUP. 1991. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Eng]. J. Med. 324: 509-516.
14. DI BISCEGLIE, A. M., P. MARTIN, C. KASSIANIDES, M. LISKER MELMAN, L. MURRAY, J. WAGGONER, Z. GOODMAN, S. M. BANKS & J. H. HOOFNAGLE. 1989. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 321:1506-1510.
15. HOOFNAGLE, J. H., M. PETERS, K. D. MULLEN, D. B. JONES, V. RUSTGI, A. DI BISCEGLIE, C. HALLAHAN, Y. PARK, C. MESCHIEVITZ & E. A. JONES. 1988. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318-1325.
16. KORENMAN, J., B. BAKER, J. WAGGONER, J. E. EVERHART, A. M. D.I. BISCEGLIE & J. H. HOOFNAGLE. 1991. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. 114:629-634.
17. LANE, H. C., J. A. KOVACS, J. FEINBERG, B. HERPIN, V. DAVEY, R. WALKER, L. DEYTON, J. A. METCALF, M. BASELER, N. SALZMAN et al 1988. Anti-retroviral effects of interferonalpha in AIDS-associated Kaposi's sarcoma. Lancet 2:1218-1222.
18. NACY, C. A., A. H. FORTIER, M. S. MELTZER, N. A. BUCHMEIER & R. D. SCHREIBER. 1985. Macrophage activation to kill Leishmania major Activation of macrophages for intracellular destruction of amastigotes can be induced by both recombinant interferon-γ and non-interferon lymphokines. J. Immunol. 144:3505-3511.
19. KIDERLEN, A., H. E. KAUFFMANN & M. L. LOHMANN-MATTHES. 1984. Protection of mice against the intracellular bacterium Listeria monocytogenes by recombinant immune interferon. Eur. J. Immunol. 14:964-967.
20. MUOTIALA, A. & P. H. MAKELA. 1990. The role of IFN-γ in murine Salmonella typhimurium infection. Microb. Pathogen. 8:135-141.
21. HOLLAND, S. M., E. M. EISENSTEIN, D. B. KUHNS, M. L. TURNER, T. A. FLEISHER, W. STROBER & J. I. GALLIN. 1994. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N. Engl. J. Med. 330: 1348-1355.
22. BADARÓ, R. & W. D. JOHNSON. 1993. The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J. Infect. Dis. 167:S13-S17.
23. KAPLAN, G. 1993. Recent advances in cytokine therapy in leprosy. J. Infect. Dis. 167: S18-S22.
24. MEUER, S. C., H. DUMANN, K. H. MEYER ZUM BUSCHENFELDE et al. 1989. Low dose interleukin-2 induces systemic immune responses against HbsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15-18.
25. QUIROGA, J. A., I. CASTILLO, J. C. PORRES, S. CASADO, F. SAEZ, M. GRACIA MARTINEZ, M. GOMEZ, L. INGLADA, L. SANCHEZ SICILIA, A. MORA et al. 1990. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 12: 661-663.
26. SHILO, M. 1959. Non-specific resistance to infection. Ann. Rev. Microbiol. 13:255.
27. CHEDID, L., M. PARANT, F. PARANT, P. LEFRANCHER, J. CHOAY & E. LEDERER. 1977. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc. Natl. Acad. Sci. USA 74:2089-2093.
28. BEUTLER, B. & A. CERAMI. 1987. Cachectin: More than a tumor necrosis factor. N. Engl. J. Med. 316:379-385.
29. BAUER, J. 1989. Interleukin-6 and its receptor during homeostasis, inflammation, and tumor growth. Klin. Wochenschr. 67:697-706.
30. VAN DER MEER, J. W. M., M. BARZA, S. M. WOLFF & C. A. DINARELLO. 1988. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram-negative infection. Proc. Natl. Acad. Sci. USA 85:1620-1623.
31. OZAKI, Y., A. OHASHI, A. MINAMI & S. NAKAMURA. 1987. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1α. Infect. Immun. 55: 1436-1440.
32. VAN DER MEER, J. W. M. 1988. The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection. Biotherapy 1:19-25.
33. VAN 'T WOUT, J. W., J. W. M. VAN DER MEER, M. BARZA & C. A. DINARELLO. 1988. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur. J. Immunol. 18:1143-1146.
34. KULLBERG, B. J., J. W. VAN 'T WOUT & R. VAN FURTH. 1990. Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infect, Immun. 58:3319-3324.
35. CZUPRYNSKI, C. J. & J. F. BROWN. 1987. Recombinant murine interleukin-1α enhancement of nonspecific antibacterial resistance. Infect. Immun. 55:2061-2065.
36. CZUPRYNSKI, C. J., J. F. BROWN, K. M. YOUNG, A. J. COOLEY & R. S. KURTZ. 1988. Effects of murine recombinant interleukin 1 alpha on the host response to bacterial infection. J. Immunol. 140:962-968.
37. McINTYRE, K. W., J. UNOWSKY, W. DELORENZO & W. BENJAMIN. 1989. Enhancement of antibacterial resistance of neutropenic bone marrow-suppressed mice by interleukin-1α. Infect. Immun. 57:48-54.
38. MINAMI, A., K. FUJIMOTO, Y. OZAKI & S. NAKAMURA. 1988. Augmentation of host resistance to microbial infections by recombinant human interleukin-1α. Infect. Immun. 56: 3116-3120.
39. GLADUE, R., A. GIRARD & M. NEWBORG. 1988. Enhanced antibacterial resistance in neutropenic mice treated with human recombinant interleukin-1 beta. Agents Actions 24: 130-136.
40. VAN DER MEER, J. W. M., R. H. RUBIN, M. PASTERNAK, D. N. MEDEARIS, P. LYNCH & C. A. DINARELLO. 1989. The in vivo and in vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection. Biotherapy 1:227-231.
41. CURFS, J. H. A. J., J. W. M. VAN DER MEER, R. W. SAUERWEIN & W. M. C. ELING. 1990. Low dosages of interleukin-1 protect mice against lethal cerebral malaria. J. Exp. Med. 172: 1287-1291.
42. FIBBE, W. E., J. W. M. VAN DER MEER, J. H. F. FALKENBURG, M. S. HAMILTON, P. M. KLUIN & C. A. DINARELLO. 1989. A single low dose of human recombinant interleukin 1 accelerates the recovery of neutrophils in mice with cyclophosphamide-induced neutropenia. Exp. Hematol. 17:805-808.
43. KULLBERG, B. J., J. W. VAN'T WOUT & R. VAN FURTH. 1991. No effect of recombinant human interleukin-1 on the numbers of peripheral blood and peritoneal leukocytes during an acute inflammation. Inflammation 15:457-470.
44. VOGELS, M. T. E., N. VAN ROOYEN, M. H. A. BEMELMANS, M. JANSEN & J. W. M. VAN DER MEER. 1994. Interleukin-1 (IL-1)-induced resistance to bacterial infection: Role of the macrophage and soluble TNF receptors. In Mechanisms of Enhanced Natural Resistance to Infection Induced by Interleukin-1. M. T. E. Vogels, Ed. Catholic University Nijmegen. Thesis.
45. KAKNO, K., Y. HIRATA, T. IMAI, M. IWASHINA & F. MARUMO. 1994. Regulation of inducible nitric oxide synthase gene by interleukin-1 beta in rat vascular endothelial cells. Am. I Physiol. 267:H2318-2324.
46. KULLBERG, B. J., J. W. VAN 'T WOUT, C. HOOGSTRATEN & R. VAN FURTH. 1993. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice. J. Infect. Dis. 168:436-443.
47. VOGELS, M. T. E., L. CANTONI, M. CARELLI, M. SIRONI, P. GHEZZI & J. W. M. VAN DER MEER. 1993. Role of acute phase proteins in interleukin-1-induced resistance to bacterial infection in mice. Antimicrob. Agents Chemother. 37:2527-2533.
48. LIBERT, C., P. BROUCKAERT & W. FIERS. 1994. Protection by alpha 1-acid glycoprotein against tumor necrosis factor-induced lethality. J. Exp. Med. 180:1571-1575.
49. VAN DER MEER, J. W. M., M. HELLE & L. AARDEN. 1989. Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 in nonspecific resistance to infection. Eur. J. Immunol. 19:413-416.
50. VOGELS, M. T. E., I. J. D. LINDLEY, J. A. H. J. CURFS, W. M. C. ELING & J. W. M. VAN DER MEER. 1993. Effects of interleukin-8 on non-specific resistance to infection in neutropenic and normal mice. Antimicrob. Agents Chemother. 37:276-280.
51. VOGELS, M. T. E., C. C. HERMSEN, H. L. P. G. HUYS, W. M. C. ELING & J. W. M. VAN DER MEER. 1994. Roles of tumor necrosis factor alpha, granulocyte-macrophage colonystimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice. Infect. Immun. 62: 2065-2070.
52. VOGELS, M. T. E., E. J. B. M. MENSINK, K. YE, O. C. BOERMAN, C. M. M. VERSCHUREN, C. A. DINARELLO & J. W. M. VAN DER MEER. 1994. Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL1-induced resistance to infection. J. Immunol. 153:5772-5780.
53. NETA, R., J. J. OPPENHEIM & S. D. DOUCHES. 1988. Interdependence of the radioprotective effects of human recombinant interleukin-1α, tumor necrosis factor-α, granulocyte colony-stimulating factor, and murine recombinant granulocyte macrophage colonystimulating factor. J. Immunol. 140:108-114.
54. WHITE, C. W. & P. GHEZZI. 1989. Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis factor. Role of antioxydant enzymes and effect of cyclooxygenase inhibitors. Biotherapy 1: 361-366.
55. JIMENEZ, J. J., G. H. W. WONG & A. A. YUNIS. 1991. Interleukin 1 protects from cytosine arabinoside-induced alopecia in the rat model. FASEB J. 5:2456-2458.
56. BROWN, J., C. W. WHITE, L. S. TERADA, M. A. GROSSO, P. F. SHANLEY, D. W. MULVIN, A. BANERJEE, G. J. R. WHITMAN, A. H. HARKEN & J. E. REPINE. 1990. Interleukin-1 pretreatment decreases ischaemia reperfusion injury. Proc. Natl. Acad. Sci. USA 87: 5026-5030.
57. PURI, R. K., W. D. TRAVIS & S. A. ROSENBERG. 1989. Decrease in interleukin 2-induced leakage in the lungs of mice by administration of recombinant interleukin-1α in vivo. Cancer Res. 49:969-976.
58. RENIC, M., F. CULO, A. BILIC, Z. BUKOVEC, D. SABOLOVIC & Z. ZUPANOVIC. 1993. The effect of interleukin 1α on acetaminophen-induced hepatotoxicity. Cytokine 5:192-197.
59. GÖRGEN, I., T. HARTUNG, M. LEIST, M. NIEHÖRSTER, G. TIEGS, S. UHLIG, F. WEITZEL & A. WENDEL. 1992. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J. Immunol. 149:918-924.